Mantle cell lymphoma · 8 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ibritumomab tiuxetan protocol Variant #18 | — | R 27 524 | 8d | ~36.5 mo | — | ~139 | ~R 3 825 804 PFS proxy · indirect | 1 |
R-BEAM Variant #01 Partial | — | R 22 812 | — | — | — | — | — | — |
BEAM Variant #01 Partial | — | R 4 294 | — | — | — | — | — | — |
BEAC N/A - secondary systemic drug | — | R 3 241 | — | — | — | — | — | — |
Cyclophosphamide and TBI Variant #01 | — | R 1 176 | — | — | 90.0 mo | — | — | 1 |
CBV N/A - secondary systemic drug Partial | — | R 43 | — | — | — | — | — | 2 |
Melphalan and TBI Variant #01 | — | R 0 | — | — | — | — | — | — |
TAM6 Variant #01 | — | R 0 | — | — | — | — | — | — |
8 of 8 regimens shown